These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 7530238

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
    Schnell R, Linnartz C, Katouzi AA, Schön G, Bohlen H, Horn-Lohrens O, Parwaresch RM, Lange H, Diehl V, Lemke H.
    Int J Cancer; 1995 Oct 09; 63(2):238-44. PubMed ID: 7591211
    [Abstract] [Full Text] [Related]

  • 3. Anti-idiotype vaccine against Hodgkin's lymphoma: induction of B- and T-cell immunity across species barriers against CD30 antigen by murine monoclonal internal image antibodies.
    Pohl C, Renner C, Schwonzen M, Sieber M, Lorenz P, Pfreundschuh M, Diehl V.
    Int J Cancer; 1992 Apr 01; 50(6):958-67. PubMed ID: 1313400
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
    Engert A, Burrows F, Jung W, Tazzari PL, Stein H, Pfreundschuh M, Diehl V, Thorpe P.
    Cancer Res; 1990 Jan 01; 50(1):84-8. PubMed ID: 2152774
    [Abstract] [Full Text] [Related]

  • 5. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
    Hombach A, Jung W, Pohl C, Renner C, Sahin U, Schmits R, Wolf J, Kapp U, Diehl V, Pfreundschuh M.
    Int J Cancer; 1993 Nov 11; 55(5):830-6. PubMed ID: 8244580
    [Abstract] [Full Text] [Related]

  • 6. CD30-specific AB1-AB2-AB3 internal image antibody network: potential use as anti-idiotype vaccine against Hodgkin's lymphoma.
    Pohl C, Renner C, Schwonzen M, Schobert I, Liebenberg V, Jung W, Wolf J, Pfreundschuh M, Diehl V.
    Int J Cancer; 1993 May 28; 54(3):418-25. PubMed ID: 8389737
    [Abstract] [Full Text] [Related]

  • 7. Idiotype vaccine against Hodgkin's lymphoma: generation and characterization of an anti-idiotypic monoclonal antibody against the Hodgkin-associated (anti-CD 30) monoclonal antibody HRS-3.
    Pohl C, Sieber M, Diehl V, Pfreundschuh M.
    Anticancer Res; 1991 May 28; 11(3):1115-24. PubMed ID: 1653553
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin.
    Hansen HP, Matthey B, Barth S, Kisseleva T, Mokros T, Davies SJ, Beckett RP, Foelster-Holst R, Lange HH, Engert A, Lemke H.
    Int J Cancer; 2002 Mar 10; 98(2):210-5. PubMed ID: 11857410
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.
    Terenzi A, Bolognesi A, Pasqualucci L, Flenghi L, Pileri S, Stein H, Kadin M, Bigerna B, Polito L, Tazzari PL, Martelli MF, Stirpe F, Falini B.
    Br J Haematol; 1996 Mar 10; 92(4):872-9. PubMed ID: 8616080
    [Abstract] [Full Text] [Related]

  • 11. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
    Pohl C, Denfeld R, Renner C, Jung W, Bohlen H, Sahin U, Hombach A, van Lier R, Schwonzen M, Diehl V.
    Int J Cancer; 1993 Jul 09; 54(5):820-7. PubMed ID: 7686889
    [Abstract] [Full Text] [Related]

  • 12. Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies.
    Franke AC, Jung D, Ellis TM.
    Hybridoma; 2000 Feb 09; 19(1):43-8. PubMed ID: 10768840
    [Abstract] [Full Text] [Related]

  • 13. Differential sensitivity of CD30+ neoplastic cells to gelonin delivered by anti-CD30/anti-gelonin bispecific antibodies.
    Sforzini S, Bolognesi A, Meazza R, Marciano S, Casalini P, Dürkop H, Tazzari PL, Stein H, Stirpe F, Ferrini S.
    Br J Haematol; 1995 Jul 09; 90(3):572-7. PubMed ID: 7646996
    [Abstract] [Full Text] [Related]

  • 14. Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphoma.
    Hansen HP, Engels HM, Dams M, Paes Leme AF, Pauletti BA, Simhadri VL, Dürkop H, Reiners KS, Barnert S, Engert A, Schubert R, Quondamatteo F, Hallek M, Pogge von Strandmann E.
    J Pathol; 2014 Mar 09; 232(4):405-14. PubMed ID: 24659185
    [Abstract] [Full Text] [Related]

  • 15. In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence.
    Falini B, Flenghi L, Fedeli L, Broe MK, Bonino C, Stein H, Dürkop H, Bigerna B, Barbabietola G, Venturi S.
    Br J Haematol; 1992 Sep 09; 82(1):38-45. PubMed ID: 1329918
    [Abstract] [Full Text] [Related]

  • 16. Targeting of saporin to Hodgkin's lymphoma cells by anti-CD30 and anti-CD25 bispecific antibodies.
    Sforzini S, de Totero D, Gaggero A, Ippoliti R, Glennie MJ, Canevari S, Stein H, Ferrini S.
    Br J Haematol; 1998 Sep 09; 102(4):1061-8. PubMed ID: 9734659
    [Abstract] [Full Text] [Related]

  • 17. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen.
    Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Pohl C, Abken H.
    J Immunother; 1999 Nov 09; 22(6):473-80. PubMed ID: 10570745
    [Abstract] [Full Text] [Related]

  • 18. A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines.
    Hansen HP, Kisseleva T, Kobarg J, Horn-Lohrens O, Havsteen B, Lemke H.
    Int J Cancer; 1995 Nov 27; 63(5):750-6. PubMed ID: 7591296
    [Abstract] [Full Text] [Related]

  • 19. The ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5.
    Hansen HP, Recke A, Reineke U, Von Tresckow B, Borchmann P, Von Strandmann EP, Lange H, Lemke H, Engert A.
    FASEB J; 2004 May 27; 18(7):893-5. PubMed ID: 15033921
    [Abstract] [Full Text] [Related]

  • 20. ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro.
    Eichenauer DA, Simhadri VL, von Strandmann EP, Ludwig A, Matthews V, Reiners KS, von Tresckow B, Saftig P, Rose-John S, Engert A, Hansen HP.
    Cancer Res; 2007 Jan 01; 67(1):332-8. PubMed ID: 17210715
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.